Pharmacokinetics of midazolam in mexicans. Evidence for interethnic variability

Clinical Drug Investigation

Volumn 17, Issue 3, 1999, Pages 233-239

  Chávez Teyes, Lilia ^a   Castañeda Hernández, Gilberto ^b   Flores Murrieta, Francisco Javier ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; MIDAZOLAM;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ETHNIC DIFFERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033046516     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917030-00008     Document Type: Article

References (27)

1. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12: 102-7
2. Daly AK, Cholerton S, Gregory W, et al. Metabolic polymorphisms. Pharmacol Ther 1993; 57: 129-60
3. Vesell ES. Genetic and environmental factors affecting drug disposition in man. Clin Pharmacol Ther 1977; 22: 659-79
4. Darmansjah I, Muchtar A. Dose response variation among different populations. Clin Pharmacol Ther 1992; 52: 449-52
5. Rashid TJ, Martin U, Clarke H, et al. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-8
6. Hoyo-Vadillo C, Castañeda-Hernández G, Herrera JE, et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816-20
7. Sowunmi A, Rashid TJ, Akinyika OO, et al. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians and South Asians. Br J Clin Pharmacol 1995, 40: 489-93
8. Castañeda-Hernández G, Palma-Aguirre JA, Montoya-Cabrera MA, et al. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996; 41: 433-4
9. Palma-Aguirre JA, González-Llaven J, Flores-Murrieta FJ, et al. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol 1997; 37: 630-4
10. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996; 59: 491-502
11. Chan K, Jones RD. Simultaneous determination of flumazenil, midazolam and metabolites in human biological fluids by liquid chromatography. J Chromatogr 1993; 619: 154-60
12. Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983; 23: 161-70
13. Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam and α-hydroxy-midazolam following rectal and intravenous administration. Br J Clin Pharmacol 1988; 25: 457-63
14. Pentikäinen PJ, Välisalmi L, Himberg J-J, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29: 272-7
15. Smith MT, Eadie MJ, Brophy TO. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981; 19: 271-8
16. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981; 30: 653-61
17. Borneman L, Crews T, Chen S, et al. Influence of food and midazolam absorption. J Clin Pharmacol 1986; 26: 55-9
18. Koopmans R, Dingemanse J, Danhof M, et al. The influence of dosage time of midazolam on its pharmacokinetics and effects in humans. Clin Pharmacol Ther 1991; 50: 16-24
19. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993; 53: 298-305
20. Kupfershmidt HT, Riem Ha H, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20-8
21. von Moltke LL, Greenblatt DJ, Schmider J, et al. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995; 29 Suppl. 1: 33-44
22. Kleinbloesem CH, Van Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 37: 2507-10
23. Breimer DD, Schellens JHM, Soons PA. Nifedipine: variability in its kinetics and metabolism in man. Pharmacol Ther 1989; 44: 445-54
24. Castañeda-Hernández G, Hoyo-Vadillo C, Palma-Aguirre JA, et al. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993; 33: 140-5
25. Ashan CH, Renwick AG, Macklin B, et al. Interethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399-403
26. Ashan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins in the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329-38
27. Rosestein Ster E. Diccionario de Especialidades Farmacéuticas, Editorial PLM S.A. de C.V., Mexico, D.F., 1998